Sign in

CIK 0001817713

  • Large accelerated filer

Janux Therapeutics, Inc.

Sign in to watch
Ticker
JANX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
822289112
Phone
+1 858-751-4493
Business address
10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 38 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-01-02 DiRaimondo Thomas Chief Scientific Officer Grant or award +24,000 129,719
2025-01-02 DiRaimondo Thomas Chief Scientific Officer Grant or award · Stock option (right to buy) +84,000 84,000
2025-01-02 Dobek Maria Vice President, Accounting Grant or award +14,000 14,001
2025-01-02 Dobek Maria Vice President, Accounting Grant or award · Stock option (right to buy) +31,500 31,500
2025-01-02 Meyer Andrew Hollman Chief Business Officer Grant or award +18,000 95,473
2025-01-02 Meyer Andrew Hollman Chief Business Officer Sale −2,922 $53.76 $157K 92,551
2025-01-02 Meyer Andrew Hollman Chief Business Officer Sale −5,768 $54.51 $314K 86,783
2025-01-02 Meyer Andrew Hollman Chief Business Officer Sale −3,444 $55.76 $192K 83,339
2025-01-02 Meyer Andrew Hollman Chief Business Officer Sale −1,000 $56.78 $57K 82,339
2025-01-02 Meyer Andrew Hollman Chief Business Officer Sale −200 $57.37 $11K 82,139
2025-01-02 Meyer Andrew Hollman Chief Business Officer Grant or award · Stock option (right to buy) +63,000 63,000
2024-12-24 Campbell David Alan President and CEO Sale 10b5-1 −25,000 $56.19 $1.4M 217,054
2024-12-19 Meyer Andrew Hollman Chief Business Officer Option exercise +9,880 $20.24 $200K 77,472
2024-12-19 Meyer Andrew Hollman Chief Business Officer Option exercise +1 $14.02 $14 77,473
2024-12-19 Meyer Andrew Hollman Chief Business Officer Option exercise · Stock Option (right to buy) −9,880 96,870
2024-12-19 Meyer Andrew Hollman Chief Business Officer Option exercise · Stock Option (right to buy) −1 89,999
2024-12-03 Campbell David Alan President and CEO Sale 10b5-1 −15,000 $67.00 $1.0M 242,054
2024-11-25 Campbell David Alan President and CEO Sale 10b5-1 −18,281 $51.43 $940K 263,773
2024-11-25 Campbell David Alan President and CEO Sale 10b5-1 −6,719 $52.04 $350K 257,054
2024-11-05 Gujrathi Sheila Director Other acquisition +4,611 115,139

Page 6 of 15 · 294 trades